看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 10.9x - 12.0x | 11.5x |
| Selected Fwd EBIT Multiple | 7.4x - 8.1x | 7.8x |
| Fair Value | €49.61 - €55.60 | €52.61 |
| Upside | -13.6% - -3.2% | -8.4% |
| Benchmarks | Ticker | Full Ticker |
| Amphastar Pharmaceuticals, Inc. | AMPH | NasdaqGS:AMPH |
| Dyadic International, Inc. | DYAI | NasdaqCM:DYAI |
| Cardiff Oncology, Inc. | CRDF | NasdaqCM:CRDF |
| Geron Corporation | GERN | NasdaqGS:GERN |
| Trevena, Inc. | TRVN | OTCPK:TRVN |
| Halozyme Therapeutics, Inc. | RV7 | DB:RV7 |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| AMPH | DYAI | CRDF | GERN | TRVN | RV7 | ||
| NasdaqGS:AMPH | NasdaqCM:DYAI | NasdaqCM:CRDF | NasdaqGS:GERN | OTCPK:TRVN | DB:RV7 | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | 42.0% | NM- | NM- | NM- | NM- | 26.0% | |
| Latest Twelve Months | -21.9% | 32.5% | -21.7% | 65.9% | 6.9% | 68.7% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 20.5% | -400.9% | -8173.8% | -22736.7% | -15325.1% | 50.4% | |
| Prior Fiscal Year | 31.0% | -282.6% | -9305.7% | -81832.9% | 13486.8% | 41.0% | |
| Latest Fiscal Year | 28.1% | -168.2% | -7123.1% | -225.6% | -1129.2% | 54.3% | |
| Latest Twelve Months | 25.1% | -131.2% | -9969.2% | -47.1% | -5880.0% | 57.9% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.52x | 6.30x | 172.87x | 3.71x | 44.63x | 7.30x | |
| EV / LTM EBITDA | 7.7x | NA | -1.7x | -7.9x | -0.8x | 11.3x | |
| EV / LTM EBIT | 10.0x | -4.8x | -1.7x | -7.9x | -0.8x | 12.6x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -7.9x | -1.7x | 10.0x | ||||
| Historical EV / LTM EBIT | 14.6x | 19.3x | 92.4x | ||||
| Selected EV / LTM EBIT | 10.9x | 11.5x | 12.0x | ||||
| (x) LTM EBIT | 683 | 683 | 683 | ||||
| (=) Implied Enterprise Value | 7,441 | 7,833 | 8,224 | ||||
| (-) Non-shareholder Claims * | (990) | (990) | (990) | ||||
| (=) Equity Value | 6,451 | 6,843 | 7,234 | ||||
| (/) Shares Outstanding | 117.0 | 117.0 | 117.0 | ||||
| Implied Value Range | 55.15 | 58.50 | 61.85 | ||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | |||
| Implied Value Range (Trading Cur) | 47.11 | 49.97 | 52.83 | 57.44 | |||
| Upside / (Downside) | -18.0% | -13.0% | -8.0% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | AMPH | DYAI | CRDF | GERN | TRVN | RV7 | |
| Enterprise Value | 1,826 | 29 | 93 | 616 | 24 | 8,856 | |
| (+) Cash & Short Term Investments | 232 | 5 | 71 | 388 | 13 | 548 | |
| (+) Investments & Other | 2 | 0 | 0 | 43 | 0 | 0 | |
| (-) Debt | (655) | (5) | (1) | (122) | (38) | (1,538) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 1,405 | 29 | 162 | 925 | 0 | 7,866 | |
| (/) Shares Outstanding | 46.5 | 36.2 | 66.5 | 638.0 | 1.0 | 117.0 | |
| Implied Stock Price | 30.21 | 0.80 | 2.44 | 1.45 | 0.28 | 67.25 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |
| Implied Stock Price (Trading Cur) | 30.21 | 0.80 | 2.44 | 1.45 | 0.28 | 57.44 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.17 | |